22.418 articles found

PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF PARKINSON'S DISEASE CONTAINING 1,2-DI[2-METHOXY-4-(2-CARBOXYLVINYL)]PHENOXYETHANE AS AN ACTIVE INGREDIENT

SHIN KYE JUNG, KIM DONG JIN, HWANG ONYOU.

· 2007-10-18

Bromocriptine versus levodopa in early Parkinson's disease.

van Hilten JJ, Ramaker CC, Stowe R, Ives NJ.

Cochrane Database Syst Rev · 2007-10-17

DOI: 10.1002/14651858.cd002258.pub2PMID: 17943771

Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.

van Hilten JJ, Ramaker CC, Stowe R, Ives NJ.

Cochrane Database Syst Rev · 2007-10-17

DOI: 10.1002/14651858.cd003634.pub2PMID: 17943795

Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats.

Borah A, Mohanakumar KP.

Cell Mol Neurobiol · 2007-10-13

DOI: 10.1007/s10571-007-9213-6PMID: 17934805

Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.

Maguire-Zeiss KA, Mhyre TR, Federoff HJ.

Exp Neurol · 2007-10-11

DOI: 10.1016/j.expneurol.2007.09.030PMID: 18035353

COMPOSITIONS THAT CONTAIN BETA-GLUCAN TO BE USED FOR THE PREVENTION AND TREATMENT OF DISEASE AND METHODS FOR THEIR USE

BARMAN SHIKHA PRAMANIK.

· 2007-10-04

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.

Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I, STRONG Study Group.

Mov Disord · 2007-10-01

DOI: 10.1002/mds.21313PMID: 17618525

Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.

Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M.

Mov Disord · 2007-10-01

DOI: 10.1002/mds.21694PMID: 17685467

Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.

Sharma R, McMillan CR, Niles LP.

J Pineal Res · 2007-10-01

DOI: 10.1111/j.1600-079x.2007.00469.xPMID: 17803521

Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study.

Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV.

Mov Disord · 2007-10-01

DOI: 10.1002/mds.21472PMID: 17853463

Levodopa-induced modifications of prosody and comprehensibility in advanced Parkinson's disease as perceived by professional listeners.

De Letter M, Santens P, Estercam I, Van Maele G, De Bodt M, Boon P, Van Borsel J.

Clin Linguist Phon · 2007-10-01

DOI: 10.1080/02699200701538181PMID: 17882694

Levodopa-induced ocular dyskinesia in Parkinson's disease.

Grötzsch H, Sztajzel R, Burkhard PR.

Eur J Neurol · 2007-10-01

DOI: 10.1111/j.1468-1331.2007.01919.xPMID: 17880568